Recent insights into SARS‐CoV‐2 omicron variant

Ribeiro da Silva, S. J., Kohl, A. , Pena, L. and Pardee, K. (2023) Recent insights into SARS‐CoV‐2 omicron variant. Reviews in Medical Virology, 33(1), e2373. (doi: 10.1002/rmv.2373) (PMID:35662313) (PMCID:PMC9347414)

[img] Text
272603.pdf - Published Version
Available under License Creative Commons Attribution.



The SARS-CoV-2 omicron variant (B.1.1.529) was first identified in Botswana and South Africa, and its emergence has been associated with a steep increase in the number of SARS-CoV-2 infections. The omicron variant has subsequently spread very rapidly across the world, resulting in the World Health Organization classification as a variant of concern on 26 November 2021. Since its emergence, great efforts have been made by research groups around the world that have rapidly responded to fill our gaps in knowledge for this novel variant. A growing body of data has demonstrated that the omicron variant shows high transmissibility, robust binding to human angiotensin-converting enzyme 2 receptor, attenuated viral replication, and causes less severe disease in COVID-19 patients. Further, the variant has high environmental stability, high resistance against most therapeutic antibodies, and partial escape neutralisation by antibodies from convalescent patients or vaccinated individuals. With the pandemic ongoing, there is a need for the distillation of literature from primary research into an accessible format for the community. In this review, we summarise the key discoveries related to the SARS-CoV-2 omicron variant, highlighting the gaps in knowledge that guide the field's ongoing and future work.

Item Type:Articles
Additional Information:This work was supported by CIHR Canada Research Chair Program (950‐231075) to K.P. and Canada's International Development Research Centre (Grant No. 109434‐001) through the Canadian 2019 Novel Coronavirus (COVID‐19) Rapid Research Funding Opportunity to K.P. and L.P. L.P. is funded by the Fiocruz Inova Program and the Foundation for Science and Technology of Pernambuco – FACEPE, Brazil (Grant No. APQ‐0560‐2.12/19). A.K. is funded by the UK Medical Research Council (MC_UU_12014/8). S.J.R.d.S. was a recipient of a Ph.D. fellowship sponsored by the Foundation for Science and Technology of Pernambuco (FACEPE) Brazil, (Grant No. IBPG‐1321‐2.12/18), and currently is supported by a Postdoctoral Fellowship sponsored by the University of Toronto, Canada.
Glasgow Author(s) Enlighten ID:Kohl, Professor Alain
Authors: Ribeiro da Silva, S. J., Kohl, A., Pena, L., and Pardee, K.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Virus Research
Journal Name:Reviews in Medical Virology
ISSN (Online):1099-1654
Published Online:04 June 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Reviews in Medical Virology 33(1):e2373
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
172630007Arthropod-borne infections and emerging virus infections in high risk areas (Programme 4)Alain KohlMedical Research Council (MRC)MC_UU_12014/8III - Centre for Virus Research